Categories: CoronavirusNews

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

NEW YORK, NY / ACCESSWIRE / August 15, 2024 / CoCrystal Pharma (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses and noroviruses, announces that management will present a company overview at the virtual Investor Summit Microcap Forum being held Tuesday, August 20, 2024. Management will be available for 1-on-1 meetings throughout the day.

Qualified investors can register here to view the live presentation and to ask questions.

Event: Q3 Investor Summit
Date: August 20th, 2024
Presentation Time: 9:00 a.m. ET (6:00 a.m. PT)
Location: WEBCAST LINK

About Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

About the Investor Summit

The Investor Summit is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. Founded in 2015.

Contact:
Fred Rockwell
fred@investorsummitgroup.com
Investor Summit Group

SOURCE: CoCrystal Pharma

View the original press release on accesswire.com

Staff

Recent Posts

Audax Private Equity to Acquire Avantor’s Clinical Services Business

SAN FRANCISCO & BOSTON--(BUSINESS WIRE)--Audax Private Equity (“Audax”) announced today it has entered into a…

42 mins ago

Enlyte Celebrates National Adjuster Day by Launching Streamlined DecisionPoint Interface

Revised system is designed to empower adjuster decision-making and increase productivity SAN DIEGO, Aug. 16,…

45 mins ago

Verantos Named to Inc. 5000 List for the Third Consecutive Year

Global leader in high-validity real-world evidence for life sciences grows more than 3x in three…

45 mins ago

Avantor® Enters into Definitive Agreement to Divest Clinical Services Business to Audax Private Equity

Accelerates ongoing business transformation and sharpens Avantor's strategic focus Strengthens balance sheet with proceeds to…

45 mins ago

CodaMetrix’s AI Platform Now Available in Epic Toolbox to Transform $20B Medical Coding Sector

CodaMetrix’s AI platform, developed with and used by 20 top U.S. health systems, efficiently and…

4 hours ago

Dr. Paul Vitenas Named on Texas Super Doctors(R) for 2024 in Texas Monthly’s 21st Year Celebration

Celebrated for His Expertise in Breast Augmentation, Facial Rejuvenation and Body Contouring, Dr. Vitenas Continues…

4 hours ago